«In this study, outcomes for HER2 -
positive lung cancer patients treated with conventional therapies were similar to outcomes for HER2 - negative patients treated in the same way.
By December 2007 Shaw had joined the clinical team testing Xalkori at Mass General and soon enrolled her first few ALK -
positive lung cancer patients.
Not exact matches
Positive discrimination is the equivalent of painting a pair of healthy
lungs on a
cancer patient.
Around 1,600 people are diagnosed with non-small cell
lung cancer in Greater Manchester every year and a proportion of these
patients will have the ALK -
positive type.
Now doctors have investigated the use of crizotinib in
patients with ALK
positive lung cancer who have not yet received any chemotherapy treatment.
A drug recently developed by Pfizer, crizotinib, targets ALK and is currently given to
patients with ALK
positive lung cancer when their
cancer has worsened after initial chemotherapy.
This will establish sequential crizotinib followed by a second generation ALK inhibitor as the standard treatment for
patients with metastatic ALK
positive lung cancer.»
«First - line immunotherapy treatment can improve survival for subset of
lung cancer patients: Results of phase III global clinical trial show that 75 percent of stage IV
lung cancer patients with both complex tumor mutations and PDL - 1
positive status respond to nivolumab.»
Though the optimal scenario is actually estimated to catch fewer
lung cancers than the criteria used in the National Lung Screening Trial (NLST) in the US, the authors predict this more stringent scenario would require fewer CT scans, and lead to fewer false positive screens and lung cancer overdiagnosis, which can lead to patient h
lung cancers than the criteria used in the National
Lung Screening Trial (NLST) in the US, the authors predict this more stringent scenario would require fewer CT scans, and lead to fewer false positive screens and lung cancer overdiagnosis, which can lead to patient h
Lung Screening Trial (NLST) in the US, the authors predict this more stringent scenario would require fewer CT scans, and lead to fewer false
positive screens and
lung cancer overdiagnosis, which can lead to patient h
lung cancer overdiagnosis, which can lead to
patient harm.
Such a
positive survival rate is encouraging considering that historically conventional RT resulted in poor tumor control for
patients with inoperable
lung cancer.
A Phase 2 Study of MM - 121 in Combination with Docetaxel versus Docetaxel Alone in
Patients with Heregulin
Positive, Locally Advanced or Metastatic Non-Small Cell
Lung Cancer
With the recent announcement that a first - line immunotherapy trial for non-small cell
lung cancer (NSCLC) is
positive for survival improvement, I can see the standard of care for
lung cancer patients radically changing over the next few years.
While «ROS1 fusion» has primarily been studied in
lung cancer, the Global ROS1 Initiative includes ROS1 -
positive (ROS1 +)
patients with melanoma and pancreatic
cancer as well.